Research programme: L1 protein - Acorda Therapeutics
Latest Information Update: 09 Mar 2010
At a glance
- Originator Acorda Therapeutics
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Spinal cord injuries
Most Recent Events
- 16 Feb 2006 No development reported - Preclinical for Spinal cord injuries in USA (unspecified route)
- 31 Jul 2000 Preclinical development for Spinal cord injuries in USA (unspecified route)